{"id":79928,"date":"2026-04-24T00:01:31","date_gmt":"2026-04-24T00:01:31","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook\/"},"modified":"2026-04-24T00:01:31","modified_gmt":"2026-04-24T00:01:31","slug":"agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/agomab-reports-full-year-2025-financial-results-and-confirms-2026-outlook\/","title":{"rendered":"Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook"},"content":{"rendered":"
\n

— Cash and Cash Investments at December 31, 2025 of \u20ac116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 —<\/p>\n

— Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn\u2019s Disease (FSCD) —<\/p>\n

— On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 —<\/p>\n

— Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of 2026 —<\/p>\n

Antwerp, Belgium, April 23, 2026<\/b> \u2013 Agomab Therapeutics NV<\/a> (Nasdaq: AGMB) (\u201cAgomab\u201d), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.<\/p>\n

\u201c2025 was a pivotal year for Agomab, with significant progress across our clinical programs and the positive topline results of the STENOVA Phase 2a study with ontunisertib in FSCD. Our momentum has continued into 2026 with positive Phase 1 results for AGMB-447 in healthy participants and the successful completion of our IPO,\u201d said Tim Knotnerus, Chief Executive Officer of Agomab. \u201cIn the second half of this year, we expect the full read-out of the OLE study with ontunisertib in FSCD as well as the topline IPF cohort data of the Phase 1b study with AGMB-447. Based on the positive regulatory interactions on trial design, we are on track to start both the Phase 2b study with ontunisertib in FSCD and Phase 2 study with AGMB-447 in IPF later this year.\u201d<\/p>\n

Pierre Kemula, Chief Financial Officer of Agomab, added, \u201cThanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.\u201d<\/p>\n

Recent Program Highlights and 2026 Anticipated Milestones<\/b>\u00a0<\/p>\n